AstraZeneca (NASDAQ:AZN) Given New $82.00 Price Target at BMO Capital Markets : vimarsana.com

AstraZeneca (NASDAQ:AZN – Free Report) had its price objective raised by BMO Capital Markets from $80.00 to $82.00 in a report published on Friday, Benzinga reports. They currently have an outperform rating on the stock. Several other brokerages have also weighed in on AZN. Morgan Stanley initiated coverage on AstraZeneca in a report on Tuesday, […]

Related Keywords

Lombard Odier Scm , , Astrazeneca Company Profile , Nemes Rush Group , Morgan Stanley , Investment Management , Astrazeneca , Pin Oak Investment Advisors Inc , Jefferies Financial Group , Table Wealth Management , Deutsche Bank Aktiengesellschaft , Free Report , Financial Group , Moderate Buy , Get Free Report , Lombard Odier , Wealth Management , Rush Group , Pin Oak Investment Advisors , Oak Investment Advisors , Astrazeneca Daily , Nasdaq Azn , Azn , Medical , Boost Price Target , Bmo Capital Markets ,